• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Management

Meta-Analysis: Myopericarditis and Vaccination

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Ling et al. (The Lancet Respiratory Medicine, 2022) characterized the incidence of myopericarditis following COVID-19 vaccination vs non-COVID-19 vaccination

METHODS:

  • Systematic review and meta-analysis
  • Study inclusion criteria
    • Studies that reported on people in the general population who had myopericarditis in temporal relation to receiving vaccines
  • Study design
    • GRADE criteria used to assess certainty of evidence
    • The primary outcome was analyzed among subpopulations, stratifying by vaccine (COVID-19 vs non-COVID-19) and age group (adult vs pediatric)
    • The effect of vaccine type (mRNA or non-mRNA), sex, age, and dose were examined
  • Primary outcome
    • Incidence of myopericarditis following vaccination

RESULTS:

  • 22 studies | 405,272,721 vaccine doses
  • Overall incidence of myopericarditis: 33.3 cases per million vaccine doses (95% CI, 15.3 to 72.6)
  • The incidence of myopericarditis did not differ significantly between people who received COVID-19 vaccines compared to those who received non-COVID vaccines (P=0.20)
    • COVID vaccines
      • 18.2 cases per million vaccine doses (95% CI, 10.9 to 30.3)
      • 11 studies (395,361,933 doses) | high certainty
    • Non-COVID vaccines
      • 56.0 cases per million vaccine doses (95% CI, 10.7 to 293.7)
      • 11 studies (9,910,788 doses) | moderate certainty
  • Compared with COVID-19 vaccination, the incidence of myopericarditis was
    • Significantly higher following smallpox vaccinations
      • 132.1 cases per million vaccine doses (95% CI, 81.3 to 214.6); P<0.0001
    • Not different after influenza vaccination
      • 1.3 cases per million vaccine doses (95% CI, 0.0 to 884.1); P=0.43
    • Not different after various other non-smallpox vaccinations
      • 57.0 cases per million vaccine doses (95% CI, 1.1 to 3036.6); P=0.58
  • Among people who received COVID-19 vaccines, the incidence of myopericarditis was significantly higher in
    • Males
    • People <30
    • People receiving an mRNA vaccine
    • People receiving a second dose (compared to a first or third dose)

CONCLUSION:

  • The overall incidence of myopericarditis was low following COVID-19 vaccination, at 18.2 cases per million doses and this incidence did not differ significantly from that of the flu vaccine
  • The incidence was highest for males, younger people, and those receiving an mRNA vaccine
  • The authors state

Our systematic review and meta-analysis shows that the incidence of myopericarditis in people who received COVID-19 vaccines was not significantly different from that in people who received non-COVID-19 vaccines in general, and was lower than that in people who received smallpox vaccines 

Learn More – Primary Sources:

Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Management Posts
Next >

Related ObG Topics:

CDC Reports on the Risk of Myocarditis with COVID-19 Vaccination
CDC Reports: The Latest on COVID-19 and Increased Risk of Myocarditis
More Data on Myocarditis Incidence Following mRNA-Based COVID-19 Vaccination
How Does Myocarditis Risk with COVID-19 Vaccination Compare to Risk associated with SARS-CoV-2 Infection?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site